Quick Answer
PharmaCyte Biotech, Inc. reported Diluted EPS of $3.19 per share for fiscal year 2025.
PharmaCyte Biotech, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $3.19 | +277.2% |
| 2024 | -$1.80 | -718.2% |
| 2023 | -$0.22 | +18.5% |
| 2022 | -$0.27 | +89.0% |
| 2021 | -$2.45 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| January 31, 2026 | -$0.17 | +61.4% | +86.3% |
| October 31, 2025 | -$1.24 | -217.9% | -0.8% |
| July 31, 2025 | -$1.23 | -164.7% | -179.5% |
| January 31, 2025 | -$0.44 | +32.3% | -12.8% |
| October 31, 2024 | -$0.39 | -50.0% | -120.5% |
| July 31, 2024 | $1.90 | +451.9% | +392.3% |
| January 31, 2024 | -$0.65 | -1525.0% | -150.0% |
| October 31, 2023 | -$0.26 | -188.9% | +51.9% |
- PharmaCyte Biotech, Inc. showed an increase of +277.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, PharmaCyte Biotech, Inc.’s diluted eps has grown by 230.2% (from $2.45 per share (loss) to $3.19 per share).
- The most recent figure is from PharmaCyte Biotech, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on August 11, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: